Allergy

Biosimilars

Cardiology

Dermatology

Endocrinology

Family Medicine

Gastroenterology

Geriatrics

Hospital Medicine

Infectious Disease

Internal Medicine

Nephrology

Neurology

Obesity Management

Ophthalmology

Pain

Pediatrics

Psychiatry

Pulmonology

Rare Disease Report®

Rheumatology

Sleep

Surgery

Women's Health

News

Media

Medical World News

Peer Exchange

Podcasts

Shows

State Of Sciences - Presentations

Videos

Webinars

Conferences

Conference Coverage

Conference Listing

Partners

CME/CE

Resources

Interactive Tools

Live Events

Press Release

Publications

Subscribe

Connor Iapoce is an associate editor for 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

Articles

Although no incidence trends were observed in a German cohort, the data indicate patients with ILD-RA have received more biological/targeted synthetic DMARDs in recent years. 




Therapy Strategies for ILD in Rheumatoid Arthritis Shifted Over Time

Lana Dykes is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LDykes@mjhlifesciences.com.

A total of 608 patients from an early RA cohort that had baseline radiographs of hands and feet, as well as at 1, 2, 5, and 8 years, were included in the long-term study. 

Study Indicated Erosion-Free Patients With Rheumatoid Arthritis Had Less Severe Disease Course 

DMARDs are the most commonly used treatment for patients with rheumatoid arthritis but have been linked with pneumonia and other pulmonary infections.

Pneumonia Risk in Patients on DMARD, Glucocorticoid Therapy for Rheumatoid Arthritis 

Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

A meta-analysis with data from more than 30 published articles provides an overview of associations between calprotectin levels and disease activity, treatment response, and inflammation among patients with rheumatoid arthritis.

Despite Research, Utility of Calprotectin as Biomarker in Rheumatoid Arthritis Still Unclear

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

About Us

Advertise

Editorial

Contact Us

Do Not Sell My Information

Privacy

Terms & Conditions

HCPLive - Clinical news for connected physicians

Facebook

Twitter

LinkedIn

Spotlight

Biosimilars Spotlight

COVID-19

Qazi Corner

This Year In Medicine 2022

Clinical

ADHD

Arterial Disease

Diabetes

Geriatric Medicine

Video Series

Insights

News Network

Peers & Perspectives

Post Conference Perspectives

 Peers & Perspective page is a resource for sit-down video interviews between expert colleagues and peers on major topics in clinical practice and research.

1rem

Peers Perspectives

Multidisciplinary Perspectives on the Management of Plaque Psoriasis 

Clinical Manifestations of Psoriatic Diseases 

Triggers of Joint Disease 

Psoriatic Arthritis: Physical and Social Burdens

Challenges in the Management of Psoriatic Arthritis

Assessing Individual Patient Needs With Plaque Psoriasis

Standard of Care: Psoriatic Arthritis and Plaque Psoriasis

Using Oral Systemic Agents for Psoriatic Arthritis Treatment

Treatment of Psoriatic Arthritis With Nonbiologic Agents

TNF Blockers as First-Line Therapy for Psoriatic Disease

IL-17, IL-23 Blockers for Treatment of Plaque Psoriasis

Looking Toward the Future in Plaque Psoriasis 

Optimizing Care With a Multidisciplinary Approach

Approaching Treatment for Patients With Psoriatic Arthritis